Alzheimer's disease.

@article{Querfurth2010AlzheimersD,
  title={Alzheimer's disease.},
  author={Henry W. Querfurth and Frank M LaFerla},
  journal={The New England journal of medicine},
  year={2010},
  volume={362 4},
  pages={
          329-44
        }
}
From the Department of Neurology, Caritas St. Elizabeth’s Medical Center, Brighton, MA (H.W.Q.); the Department of Neurology, Tufts Medical Center, Boston (H.W.Q.); the Department of Neurology, Rhode Island Hospital and the Warren Alpert Medical School at Brown University, Providence (H.W.Q.); and the Department of Neurobiology and Behavior, University of California, Irvine, Irvine (F.M.L.). Address reprint requests to Dr. Querfurth at the Department of Neurology, Rhode Island Hospital, 563… 
View on PubMed
uc.pt
1,407 Citations
Highly Influential Citations
61
Background Citations
561
Methods Citations
13
Results Citations
4

Figures from this paper

1,407 Citations

Citation Type

Citation Type

Endocrine approaches to treatment of Alzheimer's disease and other neurological conditions Part I: Some recollections of my association with Dr. Abba Kastin: A tale of successful collaboration
Age related changes in cerebrovascular reactivity and its relationship to global brain structure.
TLDR
This study aims to demonstrate the importance of knowing the carrier and removal status of canine coronavirus in the diagnosis and treatment of Alzheimer’s disease.
Is Alzheimer’s Disease a Liver Disease of the Brain?
TLDR
Evidence is presented suggesting that the liver is the origin of brain Aβ deposits and that it is involved in peripheral clearance of circulating Aβ in the blood, which means the liver could be targeted to decrease Aβ production or increase peripheral clearance.
Recent updates in the Alzheimer's disease etiopathology and possible treatment approaches: a narrative review of current clinical trials.
TLDR
The presences of a small number of candidates in the last phase suggest that a large number of candidate have had an undesirable side effect or were unable to pass essential eligibility for future phases of AD.
Alzheimer's Disease: A Clinical and Basic Science Review
TLDR
Clinical and neurobiological aspects of AD and MCI that medical students should be familiar with are emphasized and advances in the use of biomarkers for diagnosis of AD are described.
PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research
TLDR
The various PET radiotracers available for AD imaging are surveyed and discussed and their clinical applications especially in terms of early detection and cognitive relevance are discussed.
Early diagnosis and treatment of Alzheimer’s disease: new definitions and challenges
TLDR
From updated classifications and recommendations to advances in biomarkers of AD, this article aims to critically assess the literature on AD, addressing new definitions and challenges that emerged from recent studies on the subject.
New diagnostic criteria for Alzheimer ’ s disease
TLDR
Criteria for the diagnosis of probable Alzheimer’s dementia have been based on the National Institute on Aging and the Alzheimer's Association diagnostic criteria from 2011 andDSM-5 criteria from 2013, and they appear to have similar accuracy in clinical practice.
Alzheimer's disease.
Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease.
TLDR
It is concluded that DLB can be distinguished from PD, in spite of both being synucleinopathies, by CSF profiles using neurodegenerative marker analysis.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 247 REFERENCES
Molecular genetics of Alzheimer's disease.
TLDR
Evidence is shown that Alzheimer's disease is a genetically heterogeneous disorder, and new approaches are delineated in the study of the etiological and pathogenetic mechanisms of Alzheimer’s disease.
The Atorvastatin/Donepezil in Alzheimer’s Disease Study (LEADe): Design and baseline characteristics ⁎ ⁎ Roy W. Jones and Miia Kivipelto contributed equally to the content of the manuscript.
Alzheimer's disease: genes, proteins, and therapy.
TLDR
Evidence that the presenilin proteins, mutations in which cause the most aggressive form of inherited AD, lead to altered intramembranous cleavage of the beta-amyloid precursor protein by the protease called gamma-secretase has spurred progress toward novel therapeutics and provided discrete biochemical targets for drug screening and development.
Age, neuropathology, and dementia.
TLDR
The association between the pathological features of Alzheimer's disease and dementia is stronger in younger old persons than in older old persons, and age must be taken into account when assessing the likely effect of interventions against dementia on the population.
Amyloid Angiopathy–Related Vascular Cognitive Impairment
TLDR
Data from patients with CAA-related intracerebral hemorrhage suggesting associations of CAA with radiographic white matter abnormalities and cognitive impairment highlight the importance of elucidating the effects of vascular amyloid on cerebrovascular function and of developing therapeutic strategies for this potentially widespread form of microvascular cognitive impairment.
Atherosclerosis of Cerebral Arteries in Alzheimer Disease
TLDR
It is hypothesized that AD pathology is the complex end result of slowly evolving vascular disease and parenchymal lesions and important treatment options and directions for additional interventions to stave off this dementia are suggested.
Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment
TLDR
Both linear regressions and multivariate analyses correlating three global neuropsychological tests with a number of structural and neurochemical measurements performed on a prospective series of patients with Alzheimer's disease and 9 neuropathologically normal subjects reveal very powerful correlations with all three psychological assays.
National Institute of Neurological Disorders and Stroke FIVE-YEAR STRATEGIC PLAN ON MINORITY HEALTH DISPARITIES
TLDR
The NINDS has scientific interests in neurological disorders as diverse as stroke, epilepsy, multiple sclerosis, head and spinal cord injuries, Alzheimer's disease and other dementias, Parkinson's disease, neurofibromatosis, muscular dystrophy, neuroAIDS, amyotrophic lateral sclerosis, and Huntington disease.
No disease in the brain of a 115-year-old woman
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
TLDR
The loss of neuronal connectivity, indexed by loss of synapses, predicted the degree of cognitive impairment in the patients who underwent biopsy and indicated a degree of structural change in AD brain not likely to be affected by pharmacotherapy.
...
1
2
3
4
5
...